Details for New Drug Application (NDA): 062303
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
NDA 062303 describes RIFADIN, which is a drug marketed by Sanofi Aventis Us and is included in three NDAs. It is available from one supplier. Additional details are available on the RIFADIN profile page.
The generic ingredient in RIFADIN is rifampin. There are nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
The generic ingredient in RIFADIN is rifampin. There are nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
Summary for 062303
| Tradename: | RIFADIN |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | rifampin |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 062303
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 150MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
